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Allergic bronchopulmonary aspergillosis (ABPA) is a Th2 hypersensitivity lung disease in response to Aspergillus fumigatus
that aﬀects asthmatic and cystic ﬁbrosis (CF) patients. Sensitization to A. fumigatus is common in both atopic asthmatic and
CF patients, yet only 1-2% of asthmatic and 7–9% of CF patients develop ABPA. ABPA is characterized by wheezing and
pulmonary inﬁltrates which may lead to pulmonary ﬁbrosis and/or bronchiectasis. The inﬂammatory response is characterized
by Th2 responses to Aspergillus allergens, increased serum IgE and eosinophilia. A number of genetic risks have recently been
identiﬁedinthedevelopmentofABPA.These includeHLA-DRandHLA-DQ,IL-4 receptor alphachain(IL-4RA) polymorphisms,
IL-10-1082GA promoter polymorphisms, surfactant protein A2 (SP-A2) polymorphisms, and cystic ﬁbrosis transmembrane
conductance regulator gene (CFTR) mutations. The studies indicate that ABPA patients are genetically at risk to develop skewed
and heightened Th2 responses to A. fumigatus antigens. These genetic risk studies and their consequences of elevated biologic
markers mayaid in identifying asthmatic and CF patients who are at risk to the development of ABPA. Furthermore, these studies
suggestthat immunemodulationwithmedicationssuch asanti-IgE, anti-IL-4and/orIL-13monoclonalantibodies maybe helpful
in the treatment of ABPA.
1.Introduction
Allergic bronchopulmonary aspergillosis (ABPA) is a hyper-
sensitivity lung disease due to bronchial colonization by
Aspergillus fumigatus that occurs in susceptible patients
with asthma and cystic ﬁbrosis (CF). The ﬁrst published
description of ABPA as an entity came from the United
Kingdom in 1952 [1], while the ﬁrst cases in the United
States were reported a decade later [2, 3]. ABPA aﬀects
approximately 1-2% of asthmatic patients and 7–9% of
CF patients [4–6]. If unrecognized or poorly treated,
ABPA leads to airway destruction, bronchiectasis, and/or
pulmonary ﬁbrosis, resulting in signiﬁcant morbidity and
mortality.
2.Biology ofAspergillus fumigatus
A number of fungi may lead to allergic bronchopulmonary
mycoses (ABPM), but the genus Aspergillus contains the
predominant organisms causing these pulmonary disorders;
Aspergillus fumigatus is the species most commonly associ-
ated with ABPM. It is a ubiquitous, saprophytic mold found
in both outdoor and indoor air, in potting soil, crawl spaces,
compost piles, mulches, freshly cut grass, decaying vegeta-
tion, and sewage treatment facilities [7, 8]. A. fumigatus is
found worldwide including the United States, where it is
especiallyprevalentintheMidwestandEastcoast.Aspergillus
sporesarecommonindoorsandoutdoors.Aspergillus species
are thermotolerant growing at 15◦ to 53◦Ct e m p e r a t u r e s2 Clinical and Developmental Immunology
and particularly grows well at 37◦ to 40◦C which allows
for sporulation in human bronchi. Septated hyphae of
A. fumigatus are 7 to 10μm in diameter with branching at
45◦ angles. Hyphae may be demonstrated in sputum, mucus
plugs or sinus debris with Gomori methenamine-silver or
periodic acid-Schiﬀ stains.
3.Aspergillus-AssociatedPulmonaryDiseases
A. fumigatus is responsible for a variety of pulmonary dis-
eases depending on the individual’s genetic status and im-
munologic responses to Aspergillus antigens. These include:
(1) atopic asthma,
(2) invasive aspergillosis,
(3) aspergilloma (mycetoma),
(4) hypersensitivity pneumonitis,
(5) asthma,
(6) allergic bronchopulmonary aspergillosis
(a) in asthma and
(b) in cystic ﬁbrosis.
3.1.AtopicAsthma. Asthmatic patientsmay developIgE sen-
sitivity to molds including A. fumigatus.An u m b e ro f
investigators have reported that onset, persistence, and
severity of asthma are associated with sensitivity to fungus,
especially Cladosporium and Alternaria [9–15]. Recently,
David Denning’s group coined the term severe asthma
associated with fungal sensitivity (SAFS) [16]. In their
studies, sensitivity to A. fumigatus was the most common
fungus causing sensitization. Furthermore, treatment with
the antifungal agent itraconazole improved their asthma.
Another series of studies by Andrew Wardlaw’s group also
demonstrated that sensitivity to A. fumigatus was associated
with severe asthma [17]. In those studies, A. fumigatus could
be cultured from sputum specimens. FEV-1 was decreased
and total IgE levels were elevated. The asthmatic patients in
both Denning’s and Wardlaw’s studies did not fulﬁll criteria
for ABPA. Colonization with A. fumigatus and development
ofABPAalsooccursincysticﬁbrosis patients[18].Anumber
of investigators have reported that colonization with A.
fumigatus in CFis associated with decreased FEV-1and more
rapid pulmonary function decline even when not diagnosed
as ABPA. These studies suggest that there is a spectrum of
pulmonary disease states due to A. fumigatus sensitization in
asthmatic and CF patients from severe asthma to ABPA.
3.2. Invasive Aspergillosis. Invasive aspergillosis occurs in
individuals who have an iatrogenic or congenital immunod-
eﬁciency. The congenital immunodeﬁciencies are neutrophil
defects, such as chronic granulomatous disease (CGD) and
leukocyte adhesion defects (LAD). The iatrogenic defects
are secondary to chemotherapy that results in neutropenia.
In invasive aspergillosis, A. fumigatus invades the bronchial
epithelia resulting in pneumonia, tracheobronchitis, pul-
monary diseases, and pleural eﬀusions. A. fumigatus may
result in osteomyelitis and central nervous system infections.
Treatment is with antifungal medications, such as itracona-
zole, voriconazole, or posaconazole.
3.3.Aspergilloma. Aspergillomaormycetoma occursinindi-
viduals with pre-existing pulmonary diseases, such as bron-
chocentric carcinoma, cavitary tuberculosis, pulmonary
histoplasmosis, cystic ﬁbrosis, sarcoidosis, and bronchiecta-
sis. Aspergillus spores germinate in these structures forming
a tangled mass of hyphae, termed a fungus ball. Hemoptysis
is a common symptom. IgG anti-Aspergillus antibodies are
usually extremely elevated, but speciﬁc IgE anti-Aspergillus
antibodies are usually not detectable. Treatment consists of
antifungal medication and surgical excision of the cavity.
3.4. Hypersensitivity Pneumonitis. Hypersensitivity pneu-
monitis (HP) or extrinsic allergic alveolitis is caused by
a variety of antigens, including bird droppings (Pigeon
Breeder’s disease), murine urine proteins (Laboratory
Worker’s lung), thermophilic moldy hay (Farmer’s lung),
Aspergillus clavatus moldy brewery barley (Malt Worker’s
disease), and others. The symptoms in the acute stage
include fever, nonproductive cough, and dyspnea. In the
subacute stage, the symptoms are malaise, low-grade fevers,
nonproductive cough, and dyspnea. In the chronic stage,
the symptoms are chronic cough, dyspnea, fatigue, anorexia,
and weight loss. Chest radiograph displays micronodular
pulmonary inﬁltrates, ground-glass opacities, or diﬀuse
inﬁltrates. The immunologic response to the antigen isa Th1
cell-mediated reaction. IgG-speciﬁc antibodies are typically
extremely elevated. Treatment is removal of the antigen
source and corticosteroids.
4.Diagnosis and Stagingof ABPA
The diagnosis of ABPA is based on clinical and immunologic
reactivity to A. fumigatus. The minimal criteria required
for the diagnosis of ABPA are (1) asthma or cystic ﬁbrosis
with deterioration of lung function, for example, wheezing,
(2) immediate Aspergillus skin test reactivity, (3) total
serum IgE ≥1000IU/mL, (4) elevated Aspergillus speciﬁc IgE
and IgG antibodies, and (5) chest radiographic inﬁltrates
(Table 1). Additional criteria may include peripheral blood
eosinophilia, Aspergillus serumprecipitatingantibodies, cen-
tral bronchiectasis, and Aspergillus containing mucus plug
production [19–23]. The designation of ABPA-seropositive
(ABPA-S) may be used to classify asthmatic patients who
meet the required criteria but lack the proximal or central
bronchiectasis (ABPA-CB). The clinician should note that
the developmentof ABPA is not dependent on asthma sever-
ity. The diagnosis of ABPA in CF is more complicated and
disagreement exists in the literature regarding the diagnostic
criteria.Thediﬃcultyliesinthefactthattheusualcriteriafor
ABPA and the common signs and symptoms of CF overlap.
The most recent Cystic Fibrosis Foundation Consensus
Conference proposed the following diagnostic criteria: (1)
acute or subacute pulmonary deterioration not attributable
to another etiology, (2) total serum IgE > 1000IU/mL,Clinical and Developmental Immunology 3
Table 1: Criteria for diagnosis of allergic bronchopulmonary
aspergillosis in asthma.
(1) Asthma
(2) Chest radiographic inﬁltrate(s)
(3) Allergy prick skin reactivity to A. fumigatus
(4) Elevated total serum IgE level ≥1000 IU/mL. Some groups
recommend IgE ≥1000ng/mL (416IU/mL)
(5) Precipitating IgG antibodies to A. fumigatus
(6) Peripheral blood eosinophilia
(7) Elevated serum speciﬁc IgE anti-A. fumiatus antibodies
greater than twice non-ABPA IgE A. fumigatus-positive asthmatic
serum pool
(8) Elevated serum speciﬁc IgG anti-A. fumiatus antibodies
(9) Central bronchiectasis
(i) Criteria 1–9, ABPA-central bronchiectasis, ABPA-CB.
(ii) Criteria 1–8, ABPA-seropositive, ABPA-S.
(3) immediate cutaneous reactivity to Aspergillus or in vitro
speciﬁc IgE antibodies to Aspergillus, and (4) one of the
following: Aspergillus serum precipitins, elevated speciﬁc
IgG anti-Aspergillus antibodies, or new or recent chest
radiographic or chest CT abnormalities that have not cleared
with antibiotics and chest physiotherapy (Table 2)[ 23].
4.1. Clinical Staging. The spectrum of ABPA varies widely,
from individuals with mild asthma and occasional episodes
of pulmonary eosinophilia with no long-term sequelae, to
patients with ﬁbrosis, honey-comb lung, and respiratory
failure. Patterson and colleagues [22, 23] have suggested a
clinical classiﬁcation with ﬁve clinical stages of ABPA in
asthmatics (Table 3). Stage I is the initial acute stage of
ABPA with many of the typical features of the disease. In
stage II, the disease goes into remission; the inﬁltrates clear,
symptoms are reduced, and the serum IgE value will decline
by up to 35% within 6 weeks. Stage III is an exacerbation
associated with the recurrence of the initial symptoms and a
twofoldincreaseinserumIgElevels.StageIVisreachedwhen
patients need continuous corticosteroids either to control
t h e i ra s t h m ao rt op r e v e n tar e c u r r e n c eo fA B P A .S t a g eV
is the ﬁbrotic stage, which is present when there is severe
upper lobe ﬁbrosis present on the chest radiograph, and it
may be associated with honeycombing. The stage V lesions
may not respond to corticosteroids, although steroids are
often necessary to maintain a bronchodilator response, and
severe wheezing may develop if steroids are discontinued.
Pulmonaryﬁbrosisisanadvancedcomplicationthatcanlead
to pulmonary hypertension and cor pulmonale.
4.2. Radiographic Findings. There are several characteristic
radiographic abnormalities associated with ABPA [19–23].
The most common lesion is a large, homogeneous shadow
in one of the upper lobes with no change in volume. The
shadow may be triangular, lobar, or patchy, and it frequently
moves to another site. “Tram-line” shadows are ﬁne parallel
lines radiating from the hila that represent inﬂammation
Table 2: Criteria for diagnosis of allergic bronchopulmonary
aspergillosis in cystic ﬁbrosis.
Classic Diagnostic Criteria
(i) Acute or subacute clinical deterioration not attributable to
another etiology
(ii) Total serum IgE concentration greater than 1000IU/mL
unless patient is receiving corticosteroid therapy
(iii) Immediate cutaneous reactivity to Aspergillus fumigatus
while the patient is not being treated with antihistaminesor in
vitro presence of serum IgE antibody to A. fumigatus
(iv) Precipitating antibodies or serum IgG antibody to A.
fumigatus
(v)New or recent abnormalitiesonchest radiography orchest CT
that have not cleared with antibiotics and standard physiotherapy
Minimal Diagnostic Criteria
(i) Acute or subacute clinical deterioration not attributable to
another etiology
(ii) Total serum IgE concentration greater than 500IU/mL unless
patient is receiving corticosteroid therapy. If ABPA is suspected
and the total level of 200 to 500IU/mL, repeat testing in 1 to 3
months is recommended. If patient is taking steroids, repeat
when steroid treatment is discontinued.
(iii) Immediate cutaneous reactivity to Aspergillus fumigatus
while the patient is not being treated with antihistaminesor in
vitro presence of serum IgE antibody to A. fumigatus
(iv) One of the following:(a) precipitins to A. fumigatus or in
vitro documentation of IgG antibody to A. fumigates, or (b) new
or recent abnormalities on chest radiography or chest CT that
have not cleared with antibiotics and standard physiotherapy
of airway walls. Mucoid impaction causes toothpaste shad-
ows or gloved-ﬁnger shadows. Adult patients have been
reported with normal chest radiographs so radiographic
abnormalitiesarenotinvariablypresent.Intheseindividuals,
cylindrical bronchiectasis was demonstrated by tomography
or CT scan. However, central bronchiectasis is a common
complication and ﬁnding in all CF patients.
4.3. Laboratory Investigations. Laboratory tests that support
the diagnosis of ABPA are those that demonstrate allergy to
theA.fumigatus, suchaselevatedspeciﬁcIgEanti-Aspergillus
antibodies and positive Aspergillus precipitins [19–23]. The
precipitinsareonlyweaklypositivecomparedwiththestrong
reactions seen in patients with mycetomas. Culture of A.
fumigatus from the sputum is only a secondary criterion for
thediagnosisofABPA,becausealarge proportionofindivid-
uals with CF without ABPA have Aspergillus on sputum cul-
tures. Some normal individuals and many individuals with
lung diseases have small numbers of spores in their sputum;
these are probably present because of passive inhalation. The
presence of hyphae is more speciﬁc, and the presence of
eosinophils in association with hyphal elements is suggestive
of the diagnosis. The presence of eosinophilia in sputum
or blood is suggestive of ABPA in asthmatics and is a pri-
mary diagnostic criterion. The peripheral blood eosinophil
count is usually greater than 1000/mm3, and values greater
than 3000/mm3 are common. As denoted in Table 2,4 Clinical and Developmental Immunology
Table 3: Staging of allergic bronchopulmonary aspergillosis in asthmatics.
Stage IgE level Precipitins Eosinophilia IgE-Af IgG-Af Pulmonary inﬁltrates
(I) Acute +++ + + + + +
(II) Remission + ±− ± ± −
(III) Exacerbation +++ + + + + +
(IV) Corticosteroid dependent ++ ±± ± ± −
(V)Fibrotic + ±− ± ± −
eosinophilia is not a diagnostic criteria of ABPA in CF
patients. In the authors’ experience, eosinophilia is an
u n c o m m o nﬁ n d i n gi nC FA B P Ap a t i e n t s .
An increased total serum IgE level is very characteristic
of ABPA, and values may reach as high as 30,000IU/mL.
Usually, the level is greater than 1000IU/mL. Much of the
IgE is not speciﬁc to Aspergillus butis the result of polyclonal
B-cell activation. The IgE level is a very useful marker of
disease activity, and it can be used to follow outpatients
for “ﬂares”. The simple skin-prick test is a useful screening
test, as ABPA is very unlikely in patients with a negative
reaction. A dual-reaction skin test with an immediate (10–
15 minutes) and a late (4–8 hours) reaction occurs in
one third of patients with ABPA. Alternatively, serum may
be measured for the presence of speciﬁc IgE and IgG
antibodies. Patients with Aspergillus-sensitive asthma will
generally have elevated Aspergillus-speciﬁc IgE antibodies,
but patients with ABPA will have much higher Aspergillus-
speciﬁc IgE levels. Hemmann et al. [24]r e p o r t e dt h a t
ABPA and Aspergillus-sensitive patients have elevated IgE
antibodies to recombinant Aspergillus Asp f1, Asp f3, Asp f4,
and Asp f6 allergens, and that IgE levels to Asp f4 and Asp f6
is highly speciﬁc for ABPA in CF patients.
Diﬀerentiating between a bacterial ﬂare versus an ABPA
ﬂare in CF patients may be diﬃcult. A useful serum biologic
marker may be thymus and activation-regulated chemokine
(TARC) or CCL17. Latzin et al. [25]a n dH a r t le ta l .[ 26]
reported that TARC was elevated in CF patients with ABPA
and was further elevated during acute ﬂares of ABPA. TARC
is a chemokine whose ligand is CCR4 receptor on CD4+ Th2
cells.
In ABPA immunoelectrophoresis generally shows one
to three precipitin lines, often to only one extract [19–23].
Patients with aspergilloma will have multiple precipitin lines
to all antigen extracts. Extracts of A. fumigatus contain a
complex mixture of proteins that are mainly derived from
the hyphae. Antigenic composition varies between batches
according to the culture conditions, even within the same
laboratory. There is, therefore, a lack of standardization that
makes it diﬃcult to compare results between laboratories.
However, there has been some success with puriﬁcation of
the major antigenic components that may lead eventually to
improved diagnosis.
5.PulmonaryPathologyofABPA
The gross pathology of ABPA demonstrates cylindrical
bronchiectasis of the central airways, particularly those to
the upper lobes [19–23]. These airways may be occluded by
“mucoid impaction,” a condition in which large airways are
occluded by impacted mucus and hyphae. Airway occlusion
may lead to atelectasis of a segment or lobe and, if the
atelectasis is long-standing, saccular bronchiectasis may
result.Typically, ABPAisworse intheupperlobesthaninthe
lower lobes. Microscopic examination of the airways shows
inﬁltration of the airway wall with eosinophils, lymphocytes,
and plasma cells. The airway lumen may be occluded
by mucus containing hyphal elements and inﬂammatory
cells, especially eosinophils. Squamous metaplasia of the
bronchial mucosa commonly develops, and granulomas
may form. Rarely, bronchiolitis obliterans or bronchocentric
granulomatosis develops.
6.Immunopathogenesisof ABPA
As seen in Figure 1, the pathogenesis of ABPA in susceptible
personsbeginswiththeinhalationofA.fumigatussporesthat
g e r m i n a t ei n t oh y p h a ed e e pw i t h i nt h eb r o n c h i .F r a g m e n t s
of hyphae have also been found within the lung parenchyma,
potentially resulting in high concentrations of Aspergillus
allergens exposed to the respiratory epithelium and immune
system [7, 27–29]. These allergens are processed by HLA-
DR2 or HLA-DR5 bearing antigen presenting cells (APC)
and presented to T cells within bronchoalveolar lymphoid
tissue (BALT). The resulting CD4+ T cell responses to
Aspergillus are skewedtoward Th2 response with theproduc-
tion of IL-4, IL-5, and IL-13 cytokines.
6.1. Eﬀect of Aspergillus on Bronchial Epithelium. A. fumiga-
tus spores 3 to 5μm in size are inhaled and germinate deep
within the bronchi into hyphae [27]. In addition, fragments
of the hyphae can be identiﬁed within the interstitial of
the pulmonary parenchyma. The implication of this is that
there is the potential for high concentrations of A. fumigatus
allergens exposed to the respiratory epithelium and immune
system. A. fumigatus releases a variety of proteins, including
superoxide dismutases, catalases, proteases, ribotoxin, phos-
pholipases, hemolysin, gliotoxin, phthioic acid, and other
toxins. The ﬁrst line of defense against Aspergillus coloniza-
tion in the lungs is macrophage and neutrophil killing of
the conidia and the hyphae. In the development of ABPA,
Kauﬀman’s group proposed that Aspergillus proteins have a
direct eﬀect on the pulmonary epithelia and macrophage
inﬂammation [30, 31]. They demonstrated that Aspergillus
proteases induce epithelial cell detachment. In addition,Clinical and Developmental Immunology 5
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Figure 1: Proposed immunopathogenesis of ABPA. In the pathogenesis of ABPA, A. fumigatus proteases have a direct eﬀect on bronchial
epithelia causing epithelial cell damage with subsequent stimulation of cytokines and chemokines. Aspergillus proteins are processed via
HLA-DR2/DR5 bearing dendritic cells that skew the Th0 response to a Th2 response. Th2 cytokines stimulate IgE synthesis and eosinophil
activation. This leads to an eosinophilic inﬂammatory in the bronchial airways. Abbreviations: Af: Aspergillus fumigates, Asp fx: Aspergillus
fumigatus proteins, APC: antigen presenting cell, MBP: major basic protein, ECP: eosinophil cationic protein, EDN: eosinophil derived
neurotoxin, VLA: very late activation antigen, VCAM: vascular cell adhesion molecule, CxCR and CCR: chemokines receptors, MCO:
monocyte chemotactic protein, sCD23: soluble CD23, cyst-LT: cysteinyl leukotriene.
protease-containing culture ﬁltrates of Aspergillus induce
human bronchial cell lines to produce proinﬂammatory
chemokines and cytokines, such as IL-8, IL-6, and MCP-1.
Thus, various Aspergillus proteins have signiﬁcant biologic
activity that disrupts the epithelial integrity and induces
a monokine inﬂammatory response. This protease activity
allowsforenhancedallergenexposuretothebronchoalveolar
lymphoid tissue immune system. This is evident by the
bronchoalveolar lymphoid tissue synthesis of Aspergillus-
speciﬁc IgE and IgA antibodies.
An important pathogenicfeature of Aspergillus and other
microbes is their ability to interact with epithelial cells on
the mucosal surface. Macrophage and neutrophil killing of
the conidia and hyphae is the ﬁrst line of defense against
colonization in the lungs [32–35]. This is evidenced by an
increased susceptibility to invasive pulmonary aspergillosis
in patients with chronic granulomatous disease, a disorder
of phagocyte killing. A. fumigatus has several virulence
factors, includingproteolyticenzymes that can interfere with
humoral and cellular defense in the airways [36, 37]. Pro-
teases from Aspergillus and other fungi, including Alternaria
and Cladosporium, have been shown to cause epithelial
cell detachment, though Aspergillus proteases demonstrated
more activity at lower concentrations [36–39].
In addition to damaging the integrity of the epithelial
cell layer, Kauﬀman’s group demonstrated that protease
containing culture inﬁltrates of A. fumigatus induced human
bronchial cell lines to produce proinﬂammatory chemokines
and cytokines, such as monocyte chemoattractant protein
(MCP)-1, IL-8, and IL-6 [30]. MCP-1 has been impli-
cated in directly stimulating the development of Th2 cells
[40]. The cytokine-release activity could be ascribed to
the proteolytic activities of these extracts [30, 38]. These
observations suggested that proteolytic enzymes released by
Aspergillus, growing on and between epithelial cells, were
responsible for the induction of chemoattractive cytokines
by epithelial cells and the corresponding inﬂammation. It
was proposed that induction of the severe inﬂammatory
responses bythedirectactivation ofepithelialcellsmay cause
additional harm to the epithelial cell layer [36]. Destruction
of the epithelial cell barrier either by fungal proteases or
eosinophilic and neutrophilic inﬂammation was followed by
repair mechanisms, resulting in the inﬂux of serum proteins
and extracellular matrix proteins to the luminal side of
the epithelium [41]. Because spores and mycelium of A.
fumigatus have surface structures that are able to interact
with extracellular matrix molecules, damage and repair
mechanisms of the airway mucosa may facilitate the binding6 Clinical and Developmental Immunology
of Aspergillus to the damaged sites of the airways. The
enhanced release of proteolyticenzymes and allergens on the
epithelial surface would induce a continuous inﬂammatory
response and mast cell degranulation, resulting in severe and
long-lasting periods of exacerbations of ABPA.
6.2. Aspergillus-Speciﬁc Th2 Cells. The immune response to
Aspergillus antigens in ABPA patients, as well as allergic
asthmatic and CF patients, is characterized by a Th2 CD4+
T lymphocyte response [27, 42–46]. Skin test reactivity to
Aspergillus is found in 20%–25% of asthmatic patients [5,
47, 48] and 31%–59% of CF patients [24, 49]. Although
sensitization is common in these populations, only a small
percentage of patients develop ABPA.
Several groups have observed T cell lymphoproliferative
responses to crude Aspergillus extracts [42, 50–52]. Subse-
quently, Aspergillus-speciﬁc T cell responses were examined
and shown to enhance B cell IgE synthesis [52]. In addition,
Asp f1 T cell lines were generated, and the phenotypes
were found to be CD4+ CD25+ T cells with the cytokine
proﬁle IL-4+ and IFNγ−, indicating Th2 CD4+ T cells [4].
Chauhan et al. [53] subsequently developed T cell clones
from asthmatic ABPA patients and demonstrated either
Th2 (IL-4+,I F N - γ−)o rT h 0( I L - 4 +,I F N - γ+)p a t t e r n s .W e
demonstrated that ABPA subjects have increased frequency
ofIL-4+ CD3+ TcellsfromAspf2/f3/f4stimulatedperipheral
blood lymphocytes compared to Aspergillus sensitive non-
ABPA subjects [4]. IL-4 produced by T lymphocytes binds to
the IL-4 receptor (IL-4R) on B cells, and in association with
theCD40L/CD40signals,resultsinIgEisotypeswitchingand
B cell proliferation [54]. IL-4 also increases the expression
of CD86, which has been linked to eosinophilic airway
inﬂammation and airway hyperresponsiveness after allergen
challenge. A central question then is how ABPA patients
diﬀer from Aspergillus-sensitive atopic asthmatic and CF
patients. We hypothesize that ABPA develops in genetically
susceptible individuals with asthma and CF because of
increased frequency and/or activity of A. fumigatus-speciﬁc
Th2 CD4+ cells. We further propose that polymorphisms
of the interleukin-4 receptor alpha chain (IL-4RA) subunit
and HLA-DR2/DR5are the genetic susceptibility risk factors
responsible for the development of ABPA.
6.3. HLA-DR and HLA-DQ. HLA-DR restriction has been
shown to be a risk factor for the development of ABPA
(Table 4).Chauhanetal. [53, 55,56]observedthat asthmatic
and CF patients who expressed HLA-DR2 and/or DR5 but
lacked HLA-DQ2 were at increased risk for ABPA after
exposure to A. fumigatus. Within HLA-DR2 and HLA-DR5,
there are restricted genotypes. In particular, HLA-DR2HLA-
DRB1∗1501 and HLA-DRB1∗1503 genotypes were reported
to provide high relative risk. On the other hand, 40% to 44%
ofnon-ABPAatopicAspergillus-sensitive individualshavethe
HLA-DR2 and/or DR5 type. Further studies indicated that
t h ep r e s e n c eo fH L A - D Q 2 ,e s p e c i a l l yD Q B 1 ∗0201, provided
protection from the development of ABPA. Furthermore,
Chauhan et al. [53] demonstrated that Asp fl allergen has a
low-aﬃnity of binding to HLA-DR. This is consistent with
Table 4: Genetic risk factors in the development of allergic bron-
chopulmonary aspergillosis.
(i) HLA-DR restriction and HLA-DQ protection
(1) HLA-DR2
(a) HLA-DRB1∗1501 and ∗HLA-DRB1∗1503
(2) HLA-DR5
(3) HLA-DQ2 protective, decreased in ABPA
(a) DQB1∗0201
(ii) IL-4RA polymorphisms
(1) IL-4RA ile75val
(iii) IL-10 polymorphisms
(1) Promoter -1082 GG genotype
(iv) Surfactant protein A2 (SP-A2) polymorphisms
(1) SP-A2 ala91pro
(v) Cystic ﬁbrosis transmembrane conductance regulator (CFTR)
mutations
(1) Heterozygous CFTR mutations in asthmaticpatients with
ABPA
(vi) Toll-like receptor (TLR) polymorphisms
(1) TLR9 T-1237C polymorphism
Th2 T cell response previously reported by others in that
strong antigen HLA-DR-Ag-TCR aﬃnity binding favored
a Th1 cellular response whereas low-aﬃnity binding favored
a Th2 humoral response [57–61]. Four major Vβ chains, Vβ
3, 6, 13, and 14, reacted to Asp f1.
6.4. IL-4 Responses in ABPA. Human studies and murine
models have shown that CD4+ Th2 cells and their cytokines
are central to the development of ABPA [4, 43–46, 50, 62].
In particular, IL-4 has a key role in the allergic inﬂammatory
response with eﬀects on various cell populations. Its func-
tions include increasing VCAM-1 expression on endothelial
cells, which enhances the recruitment of other immune
cells, particularly eosinophils, stimulating proliferation of
ﬁbroblasts, important in airway remodeling, and increasing
Th2 diﬀerentiation while decreasing Th1 diﬀerentiation and
the production of IFN-γ [63, 64]. IL-4 also has a myriad
of eﬀects on B lymphocytes including the stimulation of
growth and activation, increasing HLA-DR class II expres-
sion important for antigen presentation, and inducing cell
surface expression of CD23 and soluble CD23. This cell
surface moleculeisthe low-aﬃnity IgE receptor(FcεRII)and
an activation marker present on a number of cells including
B cells, activated T cells, monocytes, and eosinophils. CD23
plays a role in augmenting B cell IgE synthesis through
its interactions with CD21 [65, 66]. Recently, anti-CD23
monoclonal antibody was administered to atopic asthmatic
subjects and resulted in decreased serum IgE levels [67]. In
addition, IL-4 has a more direct role in IgE isotype switching
by B-cells. It should be noted that IL-13 may also stimulate
the synthesis of IgE and is the only other cytokine that has
this capability [68–70]. Recently, increased sensitivity to in
vitroIL-4stimulationasmeasuredbyenhancedexpression ofClinical and Developmental Immunology 7
the low-aﬃnity IgE receptor (CD23) on B cells was observed
in ABPA patients [43, 44]. This was associated with single-
nucleotide polymorphisms of the IL-4 receptor alpha chain
(IL-4RA) in 92% of ABPA subjects, principally the IL-4-
binding single-nucleotide polymorphism ile75val [29, 45,
46]. This increased sensitivity to IL-4 is demonstrated by
increased expression of CD23 and CD86 on B cells of ABPA
subjects and increased CD23 expression during ﬂares of
ABPA [29]. CD23 is expressed on a variety of cells, including
B cells, natural killer cells, subpopulations of T cells, and
a subpopulation of dendritic cells. T-cell CD23 and B-cell
CD21 form a costimulatory pathway. T-cell CD28 and B-
cells CD80 and CD86 costimulatory pathways activate both
T andBcells, and CD28:CD86is important inIgE synthesis.
CD86is also found on dendritic cells that have the histamine
receptor 2, which skews antigen-speciﬁc T cells to a Th2
response. We have also observed increased CD86 expression
on monocyte-derived dendritic cells of ABPA subjects. Thus,
antigen-presenting cells such as monocytes and dendritic
cells bearing HLA-DR2 and/or HLA-DR5 and increased
sensitivity to IL-4 stimulation probably play a critical role in
skewing A. fumigatus-speciﬁc Th2 responses in ABPA.
6.5.IL-4AlphaChainReceptor(IL-4RA)Polymorphisms. The
IL-4 receptor is a type I cytokine receptor and exists as
a heterodimer that shares a subunit, IL-4 receptor alpha
chain (IL-4RA), with the IL-13 receptor alpha (IL-13RA)
[71]. There are two types of IL-4 receptors. Type I receptors,
foundonall lymphohematopoieticcells,arecomposedofthe
IL-4RA and the common gamma chain (γC), which is also
a component of IL-2, IL-7, IL-9, IL-15, and IL-21 cytokine
receptors [72]. IL-4 receptor type II, also known as the IL-
13 receptor, is formed by the association of IL-4RA with the
IL-13RA subunits and is located on immune cells, bronchial
epithelium, and vascular endothelium. IL-4 stimulates both
type I and type II receptors while IL-13 signals through type
II receptors.
A potential gain-of-function in the IL-4RA subunit may
be responsible for B cell hyper-reactivity in ABPA. As a
consequence of increased IL-4R activity, proinﬂammatory
cytokines skew T cell responses to a dominant Th2 pattern
which ultimately contributes to the pathophysiology and
progression of ABPA. There are eight naturally occurring
single nucleotide polymorphisms (SNPs) of the IL4RA
gene: ile75val, glu400ala, cys431arg, ser436leu, ser503pro,
gln576arg, ser752ala, and ser786pro reported thus far [73–
83]. Chromosome 16, which has been associated with
asthma, contains the IL-4RA gene [78]. Studies have iden-
tiﬁed a number of these SNPs to be associated with atopy
prevalence and asthma severity. In 1997 Khurana Hershey
et al. [74] initially reported on a high prevalence of atopy
and a gain-of-function in the IL-4RA as measured by
increased CD23 expression in patients with gln576arg and
a later study found that this allele correlated with asthma
severity [80]. Hershey’s group found that the presence of
two variants, val75 and arg576 together, resulted in elevated
IL-4 dependent CD23 expression which was not observed
when these SNPs were present alone [83]. In our studies,
the presence of the val75 allele, located within the IL-
4 binding region, was found in 87.5% of ABPA subjects
examined, while the cytoplasmic SNPs were present much
lessfrequentlyat27.3%forala400,27.3%pro503,and27.3%
arg576, and 9.1% arg431. Although these alleles, particularly
val75, appear to be common in the general population, their
high prevalence in ABPA suggests that they may be a risk
factor in the developmentof the disease (Table 4).
6.6. IL-10 Polymorphisms. Brouard and coworkers [84]
recently reported another genetic risk, the association of the
-1082GG genotype of the IL-10 promoter with colonization
with A. fumigatus and the development of ABPA in CF
(Table 4). The -1082GG polymorphism has been associated
with increased IL-10 synthesis; whereas the -1082A allele has
lower IL-10 synthesis. Thus, dendritic cells expressing HLA-
DR2/DR5, increased IL-10 synthesis, and increased sensitiv-
ity to IL-4 stimulation due to IL-4RA polymorphisms, may
be responsible for skewing Aspergillus-speciﬁc Th2 responses
in ABPA.
6.7. Surfactant Protein A2 (SP-A2) Polymorphisms. Recently,
Saxena et al. [85] reported that ABPA patients with poly-
morphisms (ala91pro, arg94arg) in the collagen region of
pulmonary surfactant protein A2 (SP-A2) had more elevated
total IgE levels and higher percentages of eosinophilia than
observed in those patients who lacked the SNPs (Table 4).
They also found that 80% of patients carrying both alleles
had ABPA (P = .0079, OR = 10.4), while only 50% and
60% of patients carrying each allele, individually, were ABPA
subjects, suggesting an additive eﬀect. How these SNPs
aﬀect SP-A has not yet been elucidated, but the collagen
region spanning both SNPs has been shown to associate
with receptors of alveolar macrophages [86], which are
important inprotectingagainst Aspergillus colonization[32].
It is theorized that changes in conformation or aﬃnity of
SP-A2 may decrease these interactions and compromise host
defense.
6.8. Cystic Fibrosis Transmembrane Conductance Regulator
(CFTR) Gene Mutations. Because ABPA is found in highest
incidence among atopic patients with CF, Miller et al. [87]
examined mutations in the cystic ﬁbrosis transmembrane
conductance regulator gene (CFTR) in subjects without CF
(Table 4). Their group reported that mutations were present
at a higher frequency in asthmatic patients who developed
ABPA, 6 of 21 (28.5%), versus control asthmatics, 2 of
43 (4.6%). These ABPA patients were heterozygous for the
mutations(1patientwascompoundheterozygoteandreclas-
siﬁed as atypical CF), did not have a clinical diagnosis of CF,
and had sweat chlorides <60mEq/L. Although the abnormal
airway mucus in CF is thought to be a susceptibility factor
forABPAdueto enhanced trapping ofAspergillus spores, it is
unclear what eﬀect heterozygous CFTR mutations may have
on mucus quality in asthmatic airways.
6.9. Toll-Like Receptor (TLR) Polymorphisms. Wang et al.
[88] examined Toll-like receptor (TLR) polymorphisms of8 Clinical and Developmental Immunology
TLR2, TLR4,a n dTLR9 in cavitary pulmonary aspergillosis
(CCPA), and severe asthma associated with fungal sensi-
tization (SAFS). TLR-4 is among the major receptors for
Aspergillus hyphaeandplaysanimportantpart ininnatehost
defense as TLR-4 deﬁcient mice have increased susceptibility
to invasive aspergillosis [88]. In CCPA patients, there was
signiﬁcantly increased frequency of the G allele of TLR4 on
asp299gly. ABPA patients had increased frequency of allele C
for the TLR9 T-1237C polymorphism compared to control
patients. However, in SAFS patients who are predominantly
Aspergillus sensitive, there was no association of polymor-
phisms of TLR2, TLR4,o rTLR9. TLR-9 is a receptor that
recognizes CpG motifs prevalent in bacterial and viral DNA.
Aspergillus hyphae and conidia do signal through TLR-9 on
murine neutrophils [89]. TLR-9 deﬁcient mice demonstrate
greater conidial and hyphal damage. In addition, Lazarus
et al. [90] reported that TLR9 polymorphisms have been
associated with increased risk of asthma. Novak et al.
[91] reported that the TLR9 C allele of T-1237C decreases
expression. Thus, decreased TLR-9 protective function may
be an underlying susceptibility in the development of ABPA.
There are additional genetic risk factors in the develop-
ment of allergy to fungi that include integrin β3 (ITGB3)
polymorphisms and chitinase polymorphisms. However,
they have not been examined in ABPA.
6.10. Integrin β3( I T G B 3 ) .I T G B 3encodes a β-integrin that
comprises part of the platelet and monocyte speciﬁc het-
erodimeric receptor for ﬁbrinogen and the receptor for vit-
ronectin. Gerold et al. [92] reported that vitronectin specif-
ically bound triacylated lipopeptides. Vitronectin facilitates
the delivery of lipopeptidesto the vitronectin receptor which
is part of the TLR-2 activation complex. Vitronectin binds
to 6 diﬀerent integrin receptors by an arg-gly-asp (RGD)
motif; the main receptor, though, is integrin αvβ3 (integrin
β3). Recently, Weiss et al. [93] reported single nucleotide
polymorphisms (SNP) of ITGB3 associated with asthma and
sensitization tomold allergens. BromleyandDonaldson [94]
demonstrated that the RGD peptide sequence is the ligand
for integrin β3. Whether this polymorphism is a risk factor
in the development of ABPA needs to be examined.
6.11. Chitinases. Chitin is a major structural component of
the outercoatings of many organisms such as fungi, parasitic
nematodes, and arthropods [95, 96]. Chitin has been shown
to skew the immune system towards Th1 response by sup-
pressingTh2-mediatedIgEproductionandlungeosinophilia
in allergic mice. In humans, acidic mammalian chitinase
degrade these chitins, thereby shifting the response toward
a Th2 inﬂammatory response. Elevated chitinase has been
associated with asthma and elevated IgE levels perhaps
through an IL-13 pathway [97, 98]. Furthermore, polymor-
phisms in the promoter of acidic mammalian chitinase have
been associated with atopic asthma and elevated IgE levels.
Their role in ABPA is yet to be determined.
6.12. Adhesion Molecules. Mutationof a number of adhesion
molecules has been associated with asthma and decline of
pulmonary function. However, they have not been studied
for association with sensitivity to A. fumigatus, colonization
with A. fumigatus, or development of ABPA. These include
A disintegrin and metalloprotease 33 gene (ADAM33),
ﬁlaggrin (FLG), protocadherin 1 (PCDH1), plasma uroki-
nase plasminogen activator (PLAUR), and E-cadherin genes.
These molecules play an important role in maintaining
the integrity of the airway epithelium. Kauﬀman’s group
reported that A.fumigatus andotherfungal proteasesdisrupt
bronchial epithelial integrity [30, 31]. Furthermore, Fairs
et al. [17] identiﬁed that IgE sensitization to A. fumigatus
and colonization with A. fumigatus in asthmatics was
associated with a more rapid decline of pulmonary function.
Further studies are needed to examine whether A. fumi-
gatus proteases are more damaging to bronchial epithelial
integrity when mutations of these adhesions molecules are
present.
6.13. A Disintegrin and Metalloprotease 33 Gene (ADAM33).
ADAM33isamemberoftheADAMfamily,whichisinvolved
in cell adhesion, cell fusion, cell signaling, and proteolysis.
ADAM33 is expressed on airway smooth muscle cells and
ﬁbroblasts [99, 100]. It has been proposed to contribute to
airway remodeling in asthma. SNPs of ADAM33 have been
associated with reduced lung function and rapid decline of
FEV-1 in asthma.
6.14. Filaggrin (FLG). Filaggrin contributes to the skin
barrier and mutations of FLG have been associated with
eczema. Inaddition, FLGSNPshavebeenassociated with the
development of asthma [101].
6.15. Protocadherin 1 (PCDH1). Protocadherins play an im-
portant role in cell adhesion and organ development.
Protocadherins 1 is expressed in theapical adhesion complex
of airway epithelia cells. It is postulated that PCDH1 may be
important in epithelial integrity of the airways. Koppelman
et al. [102] reported that polymorphisms of PCDH1 play a
role in the development of bronchial hyperresponsiveness in
asthma.
6.16. Plasma Urokinase Plasminogen Activator (PLAUR).
PLAUR may play a role in the pathogenesis of airway
remodeling in asthma. Barton et al. [103]reported that SNPs
of PLAUR are associated with development of asthma and
lung function decline in asthma.
6.17. E-Cadherin. E-cadherin forms cell-cell contacts pro-
moting integrity of the airway epithelium [104]. Reduction
of E-cadherin is observed during airway responses and
results in increased epithelial permeability and increased
airway hyperresponsiveness.
7.Treatment
Treatment is designed ﬁrst to control the acute episodes
and then to limit the development of chronic lung disease
[19–23].MostcasesofABPArequiretreatment withsystemicClinical and Developmental Immunology 9
corticosteroids, and the treatment of choice is prednisone.
Steroid therapy rapidly clears the eosinophilic inﬁltrates and
the associated symptoms, although it is less eﬀective at
treating mucus impaction. In asthmatic ABPA patients, the
usualstarting doseis0.5mg/kg/day,takeneachmorning,and
this dose is maintained for 2 to 4 weeks while following the
patient clinically and checking the chest radiograph for res-
olution of the acute process. After this induction treatment,
the dose of prednisone should be reduced to 0.5mg/kg given
on alternate days. If mucus impaction persists and is associ-
ated with atelectasis, bronchoscopy should be performed to
conﬁrm the diagnosis and to attempt to remove the mucus
plugs. Following resolution of the acute process, the dose of
prednisone should be reduced over 1 to 3 months. Chronic
treatment with corticosteroids is controversial, especially in
adults, because only minorities of patients with ABPA are
at risk of chronic lung disease. The relationship between
acute episodes and lung damage is unclear, and the precise
dose of prednisone is not certain, since acute exacerbations
may continue while the patients are on low doses of
steroids.
Children with ABPA usually have CF and may need
treatment with higher corticosteroid dosing and long-term
corticosteroids to prevent progressive lung damage. Stevens
et al. [23] in the Cystic Fibrosis Foundation Consensus
Conference report recommended in ABPA CF patients an
initial dose of 2mg/kg/day of prednisone for 1 week. This
is then reduced to 1mg/kg/day for 1 week that was followed
by reducing to alternate day dosing. This prednisone dose is
then gradual tapered typically. We usually maintain therapy
with a dose of 0.5mg/kg on alternate days for 3 months
and then, after 3 months, the dose of prednisone is tapered
over a further 3 months while checking the chest radiograph
and the serum IgE level for evidence of relapse. Initially, the
serum IgE level should be checked at every visit and, if the
level increases by twofold or more, the steroid dose should
be increased. We recommend that patients are followed with
serum IgE levels and chest radiographs every 6 months for
the ﬁrst 1 to 2 years, and then, if the child remains in
remission, it should be possible to reduce the frequency
of these studies. Unfortunately, this high and prolonged
corticosteroid treatment may induce diabetes in these CF
patients. Treatment with itraconazole and omalizumab
should be considered as adjunctive treatment of ABPA (see
b e l o w ) .F u r t h e r m o r e ,t h e i ru s em a yb eh e l p f u li np r e v e n t i n g
exacerbationofABPAinCFpatients. Monitoring ofABPAin
CF patients is done at multiple levels. These include clinical
symptoms of dyspnea, cough and wheezing, pulmonary
function studies, serum IgE levels, IgE and IgG speciﬁc
anti-A. fumigatus antibodies, blood eosinophilia, and blood
glucose.
The antifungal agent itraconazole has been used to
reduce the doses of steroids that are required [105, 106].
Initially, there were only open nonrandomized studies that
indicated that itraconazole is a useful adjunct to systemic
corticosteroid therapy. Two recent randomized controlled
trials have also favored intraconazole use. A double-blind,
randomized, placebo-controlled trial of itraconazole 200mg
twice daily dose resulted in decreased IgE levels and an
increase in pulmonary function and exercise tolerance.
Another randomized, controlled trial showed that treatment
of stable ABPA in adults with 400mg/day itraconazole
resulted in a signiﬁcant reduction in sputum eosinophil
count,sputumeosinophiliccationicproteinlevels,serumIgE
concentrations, and Aspergillus-speciﬁc IgG. There was also
a reduction in episodes of exacerbation requiring treatment
with systemic steroids. In the treatment of children with
ABPA, we have used a dose of 10mg/kg/day of itraconazole.
Omalizumab, anti-IgE monoclonal antibody, has been used
inuncontrolledreports.Anecdotally,ithasbeeneﬀective,but
a randomized controlled trial is necessary.
T h e r ei sn op l a c ef o ri m m u n o t h e r a p yi nc h i l d r e nw i t h
ABPA, since it is ineﬀective and potentially dangerous.
Inhaled anti-inﬂammatory agents, such as cromoglycate and
corticosteroids are not generally thought to be eﬀective.
The role of inhaled spores in the pathogenesis of ABPA is
unclear, but there is a seasonal incidence of ABPA that is
probably related to seasonal changes in mold spore counts.
Therefore, it is reasonable to advise patients with ABPA to
avoid exposure to places with high spore counts, such as
damp basements, barns, and compost heaps.
8.Prognosis
The prognosis of ABPA is good if the disease is detected
early and treatment started promptly. It is important that
the diagnosis is made and treatment commenced before
there is permanent lung damage from bronchiectasis. In
such patients, there should be no progression of the disease,
although relapses can occur many years later, and long-
term followup is recommended. In children with CF, the
relapses seem to be more frequent than they are in patients
with asthma, and careful surveillance is necessary to ensure
resolution of the disease process. In some CF patients, it
is diﬃcult to wean the steroids without an increase in
symptoms, such as dyspnea and wheezing; whether this is
due to the underlying CF lung disease or due to patients
going from stage II to stage III ABPA on withdrawal of
steroids is unclear. Symptoms are not a reliable guide to
therapy; therefore, it is important to reevaluate the chest
radiograph and the serum IgE at regular intervals until a
long-term remission is established.
9.Conclusions
ABPA occurs with a world-wide distribution in a signiﬁcant
number of patients with CF and less frequently in those
with asthma. Early diagnosis and treatment are essential in
preventingend-stageprogression. The developmentofABPA
is probably the combination of many genetic susceptibility
factors, gene-gene interactions, and environmental exposure
which work together. Understanding of the genetic risks
and immunopathogenesis of ABPA hopefully will lead
to improved early diagnosis and improved treatment of
ABPA.10 Clinical and Developmental Immunology
Abbreviations
ABPA: Allergic bronchopulmonary
aspergillosis
Af: Aspergillus fumigatus
CFTR: Cystic ﬁbrosis transmembrane
conductance regulator
IL-4RA: IL-4 receptor alpha chain
TARC: Thymus and activation-regulated
chemokine
SP-A2: Surfactant protein A2 polymorphisms.
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